Physician profile
Chanda V Banwat
NPI 1750584389
$3,382.85
in general payments reported to CMS, 2019-2025
26 companies · $954 in 2025
The $954 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $605 · 2020: $216 · 2021: $88.96 · 2022: $224 · 2023: $361 · 2024: $934 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $626.13 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $590.89 | 2019-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $519.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $345.59 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $322.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $213.50 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $142.06 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $102.70 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Teva Pharmaceuticals USA, INC. | $73.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.91 | 2019-2021 | |
| Astellas Pharma US INC | $44.87 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $44.13 | 2019 | |
| Currax Pharmaceuticals LLC | $35.18 | 2025 | Contrave |
| Kaleo, INC. | $30.95 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.11 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $23.64 | 2023 | Heplisav-B |
| Abbott Laboratories | $23.37 | 2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.48 | 2025 | Xifaxan |
| Hologic Sales and Service, LLC | $21.05 | 2019 | |
| Insmed, INC. | $20.15 | 2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $19.94 | 2020 | |
| Sobi, INC | $18.13 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.90 | 2022 | |
| Avion Pharmaceuticals | $14.37 | 2020 | |
| Sanofi Pasteur INC. | $14.06 | 2019 | |
| Bausch Health US, LLC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chanda Banwat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.